Ahmed Saadani Hassani1, Barbara J Marston, Jonathan E Kaplan. 1. *HIV Care and Treatment Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA; and †Emergency Response and Recovery Branch, Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
BACKGROUND: Cotrimoxazole (CTX) prophylaxis is among the key interventions provided to HIV-infected individuals in resource-limited settings. We conducted a systematic review of the available evidence. METHODS: MEDLINE, Embase, Global Health, CINAHL, SOCA, and African Index Medicus (AIM) were used to identify articles relevant to the CTX prophylaxis intervention from 1995 to 2014. Included articles addressed impact of CTX prophylaxis on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. We rated the quality of evidence in individual articles and assessed the overall quality of the body of evidence, the expected impact, and the cost effectiveness (CE) for each outcome. RESULTS: Of the initial 1418 identified articles, 42 met all inclusion criteria. These included 9 randomized controlled trials, 26 observational studies, 2 systematic reviews with meta-analysis, 1 other systematic review, and 4 CE studies. The overall quality of evidence was rated as "good" and the expected impact "high" for both mortality and morbidity. The overall quality of evidence from the 4 studies addressing retention in care was rated as "poor," and the expected impact on retention was rated as "uncertain." The 4 assessed CE studies showed that provision of CTX prophylaxis is cost effective and sometimes cost saving. No studies addressed impact on quality of life or HIV transmission. CONCLUSIONS: CTX prophylaxis is a cost-effective intervention with expected high impact on morbidity and mortality reduction in HIV-infected adults in resource-limited settings. Benefits are seen in both pre-antiretroviral therapy and antiretroviral therapy populations.
BACKGROUND:Cotrimoxazole (CTX) prophylaxis is among the key interventions provided to HIV-infected individuals in resource-limited settings. We conducted a systematic review of the available evidence. METHODS: MEDLINE, Embase, Global Health, CINAHL, SOCA, and African Index Medicus (AIM) were used to identify articles relevant to the CTX prophylaxis intervention from 1995 to 2014. Included articles addressed impact of CTX prophylaxis on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. We rated the quality of evidence in individual articles and assessed the overall quality of the body of evidence, the expected impact, and the cost effectiveness (CE) for each outcome. RESULTS: Of the initial 1418 identified articles, 42 met all inclusion criteria. These included 9 randomized controlled trials, 26 observational studies, 2 systematic reviews with meta-analysis, 1 other systematic review, and 4 CE studies. The overall quality of evidence was rated as "good" and the expected impact "high" for both mortality and morbidity. The overall quality of evidence from the 4 studies addressing retention in care was rated as "poor," and the expected impact on retention was rated as "uncertain." The 4 assessed CE studies showed that provision of CTX prophylaxis is cost effective and sometimes cost saving. No studies addressed impact on quality of life or HIV transmission. CONCLUSIONS:CTX prophylaxis is a cost-effective intervention with expected high impact on morbidity and mortality reduction in HIV-infected adults in resource-limited settings. Benefits are seen in both pre-antiretroviral therapy and antiretroviral therapy populations.
Authors: Andrew J Nunn; Peter B Mwaba; Chifumbe Chintu; Angela M Crook; Janet H Darbyshire; Yusuf Ahmed; Alimuddin I Zumla Journal: Trop Med Int Health Date: 2011-02-01 Impact factor: 2.622
Authors: Sándor Bereczky; Anne Liljander; Ingegerd Rooth; Lea Faraja; Fredrik Granath; Scott M Montgomery; Anna Färnert Journal: Microbes Infect Date: 2006-12-06 Impact factor: 2.700
Authors: B M Greenwood; P H David; L N Otoo-Forbes; S J Allen; P L Alonso; J R Armstrong Schellenberg; P Byass; M Hurwitz; A Menon; R W Snow Journal: Trans R Soc Trop Med Hyg Date: 1995 Nov-Dec Impact factor: 2.184
Authors: Christopher J Hoffmann; Katherine L Fielding; Salome Charalambous; Craig Innes; Richard E Chaisson; Alison D Grant; Gavin J Churchyard Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Aggrey D Mukose; Senait Kebede; Christine Muhumuza; Fredrick Makumbi; Henry Komakech; Esther Bayiga; Denis Busobozi; Joshua Musinguzi; Andreas Kuznik; Peter Stegman; Steven Forsythe; Joseph Kagaayi Journal: Biomed Res Int Date: 2020-05-18 Impact factor: 3.411
Authors: Minke H W Huibers; Imelda Bates; Steve McKew; Theresa J Allain; Sarah E Coupland; Chimota Phiri; Kamija S Phiri; Michael Boele van Hensbroek; Job C Calis Journal: PLoS One Date: 2020-02-25 Impact factor: 3.240